These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 33165869)

  • 41. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.
    Vajdy M; Srivastava I; Polo J; Donnelly J; O'Hagan D; Singh M
    Immunol Cell Biol; 2004 Dec; 82(6):617-27. PubMed ID: 15550120
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polymeric nanoparticle vaccines to combat emerging and pandemic threats.
    Wibowo D; Jorritsma SHT; Gonzaga ZJ; Evert B; Chen S; Rehm BHA
    Biomaterials; 2021 Jan; 268():120597. PubMed ID: 33360074
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nasal and pulmonary vaccine delivery using particulate carriers.
    Jia Y; Krishnan L; Omri A
    Expert Opin Drug Deliv; 2015 Jun; 12(6):993-1008. PubMed ID: 25952104
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current adjuvants and new perspectives in vaccine formulation.
    Montomoli E; Piccirella S; Khadang B; Mennitto E; Camerini R; De Rosa A
    Expert Rev Vaccines; 2011 Jul; 10(7):1053-61. PubMed ID: 21806399
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adjuvants: tailoring humoral immune responses.
    McElrath MJ
    Curr Opin HIV AIDS; 2017 May; 12(3):278-284. PubMed ID: 28257301
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
    Li WH; Su JY; Li YM
    Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Poly (lactic-co-glycolic acid) nanoparticle-based vaccines delivery systems as a novel adjuvant for H9N2 antigen enhance immune responses.
    Wusiman A; Zhang Y; Ayihengbieke T; Cheng X; Kudereti T; Liu D; Wang D; Abula S
    Poult Sci; 2022 May; 101(5):101791. PubMed ID: 35358927
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intranasal delivery of nanoparticle-based vaccines.
    Marasini N; Skwarczynski M; Toth I
    Ther Deliv; 2017 Jan; 8(3):151-167. PubMed ID: 28145824
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nanovaccines: Merits, and diverse roles in boosting antitumor immune responses.
    Yin Q; Wang Y; Xiang Y; Xu F
    Hum Vaccin Immunother; 2022 Nov; 18(6):2119020. PubMed ID: 36170662
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An overview on the role of silica-based materials in vaccine development.
    Navarro-Tovar G; Palestino G; Rosales-Mendoza S
    Expert Rev Vaccines; 2016 Nov; 15(11):1449-1462. PubMed ID: 27160927
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation.
    Renukaradhya GJ; Narasimhan B; Mallapragada SK
    J Control Release; 2015 Dec; 219():622-631. PubMed ID: 26410807
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhancement of live vaccines by co-delivery of immune modulating proteins.
    Manohar MM; Campbell BE; Walduck AK; Moore RJ
    Vaccine; 2022 Sep; 40(40):5769-5780. PubMed ID: 36064671
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advances and Potential Applications of Chitosan Nanoparticles as a Delivery Carrier for the Mucosal Immunity of Vaccine.
    Li D; Fu D; Kang H; Rong G; Jin Z; Wang X; Zhao K
    Curr Drug Deliv; 2017; 14(1):27-35. PubMed ID: 27494157
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates.
    Li H; Monslow MA; Freed DC; Chang D; Li F; Gindy M; Wang D; Vora K; Espeseth AS; Petrovsky N; Fu TM
    Vaccine; 2021 Dec; 39(51):7446-7456. PubMed ID: 34852943
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA.
    Carson CS; Becker KW; Garland KM; Pagendarm HM; Stone PT; Arora K; Wang-Bishop L; Baljon JJ; Cruz LD; Joyce S; Wilson JT
    J Control Release; 2022 May; 345():354-370. PubMed ID: 35301055
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Suppressing Subcapsular Sinus Macrophages Enhances Transport of Nanovaccines to Lymph Node Follicles for Robust Humoral Immunity.
    Zhang YN; Poon W; Sefton E; Chan WCW
    ACS Nano; 2020 Aug; 14(8):9478-9490. PubMed ID: 32479046
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
    Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
    Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nanoalum adjuvanted vaccines: small details make a big difference.
    Raponi A; Brewer JM; Garside P; Laera D
    Semin Immunol; 2021 Aug; 56():101544. PubMed ID: 34895823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague.
    Kilgore PB; Sha J; Hendrix EK; Motin VL; Chopra AK
    mBio; 2021 Dec; 12(6):e0322321. PubMed ID: 34872353
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Administration Routes of Polyethylenimine-Coated PLGA Nanoparticles Encapsulating Angelica Sinensis Polysaccharide Vaccine Delivery System Affect Immune Responses.
    Gu P; Zhang Y; Cai G; Liu Z; Hu Y; Liu J; Wang D
    Mol Pharm; 2021 Jun; 18(6):2274-2284. PubMed ID: 33926191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.